|
Impact of tumor-infiltrating lymphocytes on response to neoadjuvant chemotherapy in triple-negative early breast cancer: Translational subproject of the WSG-ADAPT TN trial. |
|
|
Honoraria - Amgen; AstraZeneca; Celgene; Eisai; Gedeon Richter; Genomic Health; GlaxoSmithKline; Novartis; Pierre Fabre; Puma Biotechnology; Roche; Teva |
Consulting or Advisory Role - Genomic Health; Novartis; Pierre Fabre; Roche; Teva |
Speakers' Bureau - Genomic Health |
Research Funding - Boehringer Ingelheim; Eisai; Novartis; Roche |
Travel, Accommodations, Expenses - Celgene; Daiichi Sankyo; PharmaMar; Roche; Teva |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Celgene; Daiichi Sankyo; Novartis; Roche |
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Celgene; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Genomic Health; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Genomic Health; Roche |
Travel, Accommodations, Expenses - Celgene |
|
|
Honoraria - Amgen; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech; Sandoz |
Research Funding - Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |